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Introduction
Coronary artery disease (CAD) is a pathological pro-
cess characterized by atherosclerotic plaque accu-
mulation in the coronary arteries, which may lead to 
coronary luminal narrowing and ischemia (1). CAD is 
the most prominent cause of morbidity and mortality 
in Western societies, accounting for approximately 7.4 
million (13%) deaths per year (2). Since many CAD pa-
tients are asymptomatic, the first manifestation is ge-
nerally myocardial infarction or sudden cardiac death 
(3). Therefore, there is an emerging need for improved 
screening tools for subclinical coronary atherosclero-
sis, which is a strong predictor of future adverse cardio-
vascular events (4–7). With the help of non-contrast en-
hanced low dose cardiac computed tomography (CT) 
scans, we can quantify the amount of coronary artery 
calcification (CAC). CAC scoring is a robust method to 
detect and quantify CAD particularly in those without 
any symptom (8). This review aimed to summarize the 
prognostic role of CAC scoring in individualized risk 
prediction and guiding preventative therapies.
Detection of coronary artery calcification
Several CAC scoring systems have been described. 
Among them, the Agatston score is considered as the 
gold standard for the quantification of CAC. Agatston 
score is based on the weighted density score given 
Coronary CT angiography (CCTA) has emerged as a gatekeeper to rule out coronary artery disease (CAD), due to its 
high sensitivity and negative predictive value. Prior to CCTA a native calcium screening scan is acquired, which provi-
des additional information about the coronary artery anatomy and cardiovascular risk prediction by measuring coronary 
artery calcification (CAC).
Based on large population-based and cohort studies, zero CAC score is linked to low probability of cardiovascular events in 
the future. Moreover, zero CAC score is superior in the discrimination and risk reclassification when compared with other car-
diovascular risk factors. CAC score can also help to identify those who are less likely to benefit from statin pharmacotherapy.
Since CAC score has an important role in risk stratification and it is a cheap and widely accessible non-invasive imaging 
modality, the major guidelines have already incorporated CAC score for risk prediction and therapy guiding. However, 
these guidelines give slightly different recommendations. Therefore, this review aimed to introduce the CAC measu-
rement and to summarize the prognostic role of CAC scoring in individualized risk prediction and guiding preventative 
therapies.
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to the highest attenuation value (HU) multiplied by the 
area of the calcification speck (9). This scoring system 
has been adapted to the current multidetector CT, which 
is still the most widely used imaging modality to detect 
and calculate CAC score (10). Representative example 
of a CAC score measurement can be seen in Figure 1.
Beyond Agatston score, calcium volume score and re-
lative calcium mass score can be used for the quan-
tification of the extent of coronary artery calcification. 
Calcium volume score has proven to be the most ro-
bust and reproducible method (11). It is calculated by 
multiplying the number of voxels with calcification by the 
volume of each voxel, including all voxels with an atte-
nuation >130 HU. However, this method is particularly 
sensitive to the partial volume effect. Relative calcium 
mass score is calculated by multiplying the mean atte-
nuation of the calcified plaque by the plaque volume in 
each image, thus reducing the variation caused by the 
partial volume. The absolute calcium mass score uses a 
correction factor based on the attenuation of water (11).
Prognostic value of CAC score
Several population-based and cohort studies have in-
vestigated the prognostic value of CAC score in the 
prediction of CAD.
In 2007 Budoff et al. reported that based on their lar-
ge cohort study of 25,253 asymptomatic individuals, 
CAC was an independent predictor of mortality after 
adjustment for age, sex, ethnic background, smoking, 
diabetes mellitus, positive family history for premature 
CAD, hypertension and hypercholesteraemia. Regar-
ding the 10-year follow-up, in those with zero CAC, the 
survival was 99.4%, while in those with >1000 CAC, it 
decreased to 87.7% (p<0.0001) (Figure 2) (12). Another 
FIGURE 1. CAC score measurement with a semi-automated software. A: As a first step, the software automatically recognize 
and mark high-density areas of at least 1 mm2-with >130 Hounsfied units or ≥ 3 adjacent pixels (9). B: We can manually assign 
calcified plaques to the corresponding coronary arteries. The program calculates several vessel-based and total CAC parame-
ters, such as CAC score, area or volume
FIGURE 2. Risk-adjusted cumulative survival by CAC score. 
Adopted from Budoff MJ et al (12)
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cohort study of 9715 asymptomatic patients reported 
that the extent of CAC could accurately predict 15-year 
mortality in the study population (13). Based on a large 
prospective, population-based study of 6809 individu-
als between 45 and 84 years, the relationship between 
CAC and CAD was similar in young and elderly parti-
cipants, suggesting that CAC scoring is a useful tool for 
risk prediction regardless of age (14).
The prospective cohort MESA (Multi-Ethnic Study of 
Atherosclerosis) study investigated the distribution of 
CAC on the basis of age, sex, ethnic background in in-
dividuals without clinically manifest cardiovascular di-
sease. Based on their analysis of 6110 included parti-
cipants, higher CAC values were measured in men, and 
CAC score increased with increasing age. Moreover, 
when studying the sex-, race and age-based differen-
ces, whites had the highest percentiles in all age group 
and Chinese had the lowest percentiles in the oldest 
age group regardless of sex. In younger participants, 
Hispanic women and black men had the lowest percen-
tiles (15). This study provided the “CAC Score Referen-
ce Values” for the estimation of CAC score based on 
age, gender and race.
Another MESA Study of 6814 participants aimed to di-
rectly compare six risk markers including CAC, carotid 
intima-media thickness, ankle-brachial index, brachial 
flow-mediated dilatation, high-sensitivity C-reactive pro-
tein and family history of CAD (16). Their results suggest 
that CAC is superior in the discrimination and risk reclas-
sification when compared with the other five markers.
In 2015 McClelland et al derived and validated a novel 
risk score for the estimation of 10-years CAD risk (MESA 
risk score) (17). Beyond traditional Framingham risk fac-
tors such as age, sex, HDL cholesterol, total cholesterol, 
systolic blood pressure, anti-hypertensive medication 
use, current smoking and diabetes, MESA risk score 
included CAC score, as well. External validation for test-
ing MESA risk score was conducted in the Heinz Nixdorf 
Recall Study (HNR) and in the Dallas Heart Study (DHS) 
populations. Their results have shown that when adding 
CAC score to the traditional risk factors, C-statistic imp-
roved from 0.75 to 0.80 (p<0.0001). MESA risk score 
proved to be a very accurate tool for the estimation of 
10-year CAD risk: external validation analysis resulted in 
0.779 Harrell’s C-statistic in HNR and 0.816 in DHS. Until 
now, only MESA risk score incorporated CAC testing in 
the risk prediction of CAD.
The predictive value of zero CAC score
Previous studies aimed to investigate the utility of zero 
CAC score in the risk stratification of patients with 
suspected CAD (18–25). All of them concluded that 
zero CAC score is linked to low probability of cardio-
vascular events in the future.
In a study including 6814 MESA participants, zero CAC 
score proved to be the strongest among all negative risk 
markers, with an adjusted mean diagnostic likelihood 
ratio of 0.14±0.12 for CAD (Figure 3). Moreover, in net 
reclassification improvement analysis, zero CAC sco-
re resulted in the largest and most accurate downward 
risk reclassification (26). Another MESA study of 4758 
participants, among those by whom moderate-to-high 
intensity statin therapy was recommended based on 
2013 ACC/AHA guidelines, 41% had zero CAC and 5.2 
atherosclerotic cardiovascular disease event rate of 5.2 
per 1000 person-years (23). Absence of CAC was lin-
FIGURE 3. Risk factor-adjusted diagnostic likelihood ration 
of negative risk markers for cardiovascular disease events 
(26). Abbreviations: ABI: ankle-brachial index; CAC: coro-
nary artery calcium; cIMT: carotid intima-media thickness; 
hsCRP: high sensitivity C-reactive protein
TABLE 1. Recommendation of the major societies on the use of CAC testing for risk assessment of asymptomatic patients (28–30)
Class of 
recommen-
dation
Level 
of evi-
dence
Recommendations
2016 ESC IIb B CAC scoring may be considered as a risk modifier for cardiovascular risk assessment.
2017 SCCT I B It is appropriate to perform CAC scoring for asymptomatic patients without clinical ASCVD who are between 40–75 years of age with a ten-year ASCVD risk of 5–20%.
2018 ACC/AHA IIa B
CAC testing can be considered between 40–75 years of age with intermediate risk 
to guide statin therapy if risk estimate do not clearly favour initiation of statin therapy. 
Preventive pharmacotherapy is recommended >100 CAC score.
Abbreviations: ACC: American College of Cardiology; AHA: American Heart Association; ASCVD: atherosclerotic cardiovascular disease; CAC: coronary 
artery calcium; ESC: European Society of Cardiology; SCCT: Society of Cardiovascular Computed Tomography.
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ked to extremely low CAD rate in the Population-based 
cohort of JUPITER (Justification for Use of Statins in 
Prevention: An Intervention Trial Evaluating Rosuvasta-
tin) Study, as well (27).
Therefore, zero CAC score can help to identify those 
who are less likely to benefit from statin and other pre-
ventive pharmacotherapy.
The role of CAC score in primary prevention
Since CAC screening has emerged as a relatively 
cheap and widely accessible non-invasive imaging mo-
dality, the major guidelines and expert consensus do-
cuments have already incorporated CAC score for risk 
prediction and therapy guiding (Table 1).
The 2016 European Society of Cardiology (ESC) guide-
line on cardiovascular disease prevention recommends 
that CAC testing may be considered as a risk modifier 
for cardiovascular risk assessment (28). The 2017 ex-
pert consensus of the Society of Cardiovascular Com-
puted Tomography (SCCT) states that it is appropriate 
to measure CAC score for shared decision making in 
patients without symptoms of CAD who are between 
40-75 years of age and with 5-20% ten-year risk of 
athe rosclerotic cardiovascular disease. In those indi-
viduals with lower risk, CAC testing may be considered 
in selected cases, such as in those with family history 
of premature CAD (29). The 2018 ACC/AHA choles-
terol guideline recommends that CAC scoring can be 
considered between 40–75 years of age with interme-
diate risk to guide statin therapy if risk estimate do not 
clearly favor initiation of statin therapy. In case of zero 
CAC, it is reasonable to withhold statin and initiation of 
preventive pharmacotherapy is recommended for those 
patients with >100 CAC score (30).
The difference in the recommendations of the various 
societies can be explained by several facts. Since the 
ESC guideline was published in 2016, it does not include 
the most recent study results, while the 2018 ACC/AHA 
cholesterol guideline is based on more recent data sup-
porting the use of CAC in therapy guidance (18, 31–33). 
The expert consensus of the SCCT places the greatest 
emphasis on the role of CAC score in patient manage-
ment among the three societies. How ever, the SCCT 
document is an expert consensus, which does not have 
the same requirements as a guideline and therefore it 
can be more progressive.
In Hungary, unfortunately, CAC scoring is not used for 
risk stratification in asymptomatic patients despite the 
strong supporting evidences. Coronary calcium scan is 
routinely acquired before each CCTA in symptomatic 
patients with suspected CAD. The non-contrast enhan-
ced scan is used mainly for planning the CCTA image 
acquisition and in some cases to defer from CCTA due 
to very high CAC score. High CAC score values are 
associated not only with elevated cardiovascular risk, TA
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but they can cause artifacts resulting in non-diagnos-
tic CCTA images. However, there are no clear-cut CAC 
score thresholds above which performance of CCTA 
is not recommended therefore it depends on the local 
expertise and the clinical question to decide if CCTA 
should be deferred. We have previously determined in-
dividualized cut-off values for given probabilities of the 
need of additional testing, which may facilitate perso-
nalized decision-making to perform or defer coronary 
CTA (Table 2) (34).
CAC screening appears to improve cooperation of 
asymp tomatic patients (21). A meta-analysis of six stu-
dies concluded that identification of CAC was associ-
ated with significantly increased likelihood of initiating 
and continuing pharmacologic and lifestyle CAD pre-
vention (35).
Limitations of CAC score-based risk  
prediction
Agatston score does not provide information about 
the total number and regional distribution of calcified 
plaques, which would be an important aspect of CAD 
risk prediction (36–38). Moreover, calcified plaques 
seem to be more resistant to rupture when compared 
with non-calcified or partially-calcified coronary arte-
ry lesions. Therefore, even if increased plaque density 
contributes to higher CAC score values and increased 
cardiovascular risk, previous studies have reported that 
for the same plaque volume, higher calcium density is 
linked to decreased risk of CAD (5, 39). Similarly, since 
statins can reduce the volume of non-calcified plaque 
components, it may lead to higher CAC score parallel 
with increased plaque stability (ie. paradox calcifica-
tion) (40, 41).
Even if absence of CAC proved to be a strong nega-
tive marker, the CAD risk remains high in some special 
cases. In asymptomatic patients with zero CAC score, 
after adjustment for age and sex, positive family histo-
ry for CAD was associated with 73% increase in CAD 
(42). Similarly, in those individuals with zero CAC score, 
mortality hazard ratio was 3.6 (95% CI: 2.3–5.7) in ac-
tive smokers compared to non-smokers (43). Moreover, 
in MACS (Multicenter AIDS Cohort Study), HIV infecti-
on was associated with higher prevalence of non-cal-
cified coronary artery plaque independent of other car-
diovascular risk factors (44).
Conclusion
In this review we aimed to summarize the most impor-
tant data on the prognostic value of CAC scoring in 
asym ptomatic patients and its role in primary preven-
tion. Based on the results of large population-based 
and cohort studies, CAC scoring is highly encouraged 
for further risk stratification for decision making on ini-
tiation of preventive pharmacotherapy. Moreover, CAC 
scoring can improve cooperation of patients and adher-
ence to statins. For all these reasons, the major guide-
lines and expert consensus documents have already 
incorporated consideration of CAC testing into CAD risk 
stratification and therapy guiding. However, it is impor-
tant to keep in mind, that CAC score can only identify 
calcified plaque components, while non-calcified coro-
nary artery lesions cannot be excluded without CCTA. 
All in all, given the burden of CAD both on the patients 
and healthcare, utilizing CAC testing in asymptomatic 
patients for the purpose of primary prevention and risk 
stratification should be considered.
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